Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
New York Genome Center | RCV000758715 | SCV001441383 | pathogenic | Holoprosencephaly sequence | 2020-02-06 | criteria provided, single submitter | clinical testing | The c.1603C>T (p.Arg535Cys) variant identified in the CNOT1 gene substitutes a highly conserved Arginine for Cysteine at amino acid 535/2377 (coding exon 14/49).This variant is absent from gnomAD suggesting it is not a common benign variant in the populations represented in this database. In silico algorithms predict this variant to be Deleterious (Provean; score: -6.83) and Damaging (SIFT; score: 0.000) to the function of the canonical transcript. This variant is reported as both Pathogenic and as a Variant of Uncertain Significance in ClinVar (VarID:619606). The p.Arg535Cys variant identified in this individual has been reported in five unrelated individuals with holoprosencephaly confirmed by MRI [PMID:31006513; PMID:31006510], or clinical features consistent with holoprosencephaly [PMID:31006513]. This variant was identified de novo in an individual submitted for clinical WGS. The c.1603C>T (p.Arg535Cys) variant identified in the CNOT1 gene is reported as Pathogenic. |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV000787479 | SCV002512576 | pathogenic | Holoprosencephaly 12 with or without pancreatic agenesis | 2021-05-13 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PS4 moderate, PM1, PM2, PM6 very strong |
Muenke lab, |
RCV000758715 | SCV000887489 | uncertain significance | Holoprosencephaly sequence | flagged submission | clinical testing | ||
OMIM | RCV000787479 | SCV000926444 | pathogenic | Holoprosencephaly 12 with or without pancreatic agenesis | 2020-09-29 | no assertion criteria provided | literature only |